🇺🇸 FDA
Pipeline program

Vyndaqel 61 mg soft capsules

MGNT2022

Approved small_molecule active

Quick answer

Vyndaqel 61 mg soft capsules for Transthyretin cardiac amyloidosis is a Approved program (small_molecule) at Monte Rosa Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Monte Rosa Therapeutics
Indication
Transthyretin cardiac amyloidosis
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials